Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.
Journal for ImmunoTherapy of Cancer · 2026-02 · 14 (2) · e012886
DOI: 10.1136/jitc-2025-012886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 04.02.2026. Verfasst von Shougeng Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, B7-H1 Antigen, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Basic Scientific Research Project of Department of Education of Liaoning Province, International Industrial Technology Research and Development Project of Liaoning Provincial Department of Science and Technology.
Abstract (Originalsprache)
Background
Acquired resistance to KRAS G12C inhibitor sotorasib remains a critical challenge in non-small cell lung cancer treatment. A deeper, rational understanding of resistance mechanisms can enable the development of therapeutic strategies to overcome resistance.
Methods
We established a syngeneic resistant model after prolonged AMG-510 treatment in C57BL/6 mice. In addition, the in vitro co-culture model and multiple methods including flow cytometry and western blot were used to assess the changes of immune microenvironment during resistance. Finally, a serial combinatorial therapy strategy was applied in the resistant mouse model to evaluate its ability to reverse resistance.
Results
Upregulation of PD-L1 in KRAS G12C tumors drives an immunosuppressive tumor microenvironment and promotes acquired resistance characterized by reduced infiltration of cytotoxic CD8 + T cells and a marked expansion of myeloid-derived suppressor cells through JAK2/STAT3/IL-6 Pathway. These mechanisms promote tumor immune evasion and protection from cell apoptosis, thereby establishing a microenvironment that sustains acquired resistance to sotorasib. Critically, sequential administration of a PD-L1 inhibitor (PD-L1i) effectively reprogrammed the immunosuppressive microenvironment, restoring antitumor immunity and re-sensitizing resistant tumors to sotorasib treatment.
Conclusions
These results identify the PD-L1-driven immunosuppressive microenvironment as a key mediator of sotorasib resistance and propose PD-L1i as a synergistic strategy to overcome resistance, which warrants clinical exploration of sequential or combinatorial regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
- Benxi Institute of Pharmaceutical Research, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
- Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China lhwang@syphu.edu.cn elanorzhang@163.com cuiwei@syphu.edu.cn.
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning, China lhwang@syphu.edu.cn elanorzhang@163.com cuiwei@syphu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Basic Scientific Research Project of Department of Education of Liaoning Province
- International Industrial Technology Research and Development Project of Liaoning Provincial Department of Science and Technology
Zitieren
APA
Liu, S., Jiang, Y., Fu, Y., Wang, S., Fu, R., Gao, M., Zhao, Y., Chen, S., Yang, Y., Yang, W., Jia, L., Qin, M., Zhang, X., Cui, W., & Wang, L. (2026). Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression. Journal for ImmunoTherapy of Cancer, 14(2), e012886. https://doi.org/10.1136/jitc-2025-012886
Vancouver
Liu S, Jiang Y, Fu Y, Wang S, Fu R, Gao M, et al. Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression. Journal for ImmunoTherapy of Cancer. 2026;14(2):e012886. doi:10.1136/jitc-2025-012886
BibTeX
@article{Liu2026,
author = {Liu, Shougeng and Jiang, Yiting and Fu, Yudong and Wang, Simeng and Fu, Rao and Gao, Minmin and Zhao, Yingxi and Chen, Sihong and Yang, Yuan and Yang, Weiming and Jia, Lina and Qin, Mingze and Zhang, Xiaohui and Cui, Wei and Wang, Lihui},
title = {Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {2},
pages = {e012886},
doi = {10.1136/jitc-2025-012886}
}
EUVIMED